Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Bottomly

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Cell Reports. Medicine|December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemiaMelissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Cancer Research|December 19, 2015
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisJulia E Maxson, Melissa L Abel, Jinhua Wang, et al.
Frontiers in Immunology|December 25, 2025
The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitorJennifer N Saultz, Daniel Bottomly, Faith Burns, et al.
G3 (Bethesda, Md.)|March 3, 2012
Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross miceDaniel Bottomly, Martin T Ferris, Lauri D Aicher, et al.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid LeukemiaRucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Plos Pathogens|March 8, 2013
Modeling host genetic regulation of influenza pathogenesis in the collaborative crossMartin T Ferris, David L Aylor, Daniel Bottomly, et al.
Blood|February 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemiaBasil Allen, Daniel Bottomly, Thomas Köhnke, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Cell Reports. Medicine|December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemiaMelissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Cancer Research|December 19, 2015
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisJulia E Maxson, Melissa L Abel, Jinhua Wang, et al.
Frontiers in Immunology|December 25, 2025
The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitorJennifer N Saultz, Daniel Bottomly, Faith Burns, et al.
G3 (Bethesda, Md.)|March 3, 2012
Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross miceDaniel Bottomly, Martin T Ferris, Lauri D Aicher, et al.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid LeukemiaRucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Plos Pathogens|March 8, 2013
Modeling host genetic regulation of influenza pathogenesis in the collaborative crossMartin T Ferris, David L Aylor, Daniel Bottomly, et al.
Blood|February 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemiaBasil Allen, Daniel Bottomly, Thomas Köhnke, et al.
Pageof 6